Home
About
Intelligent miRNA therapeutics for cancer
| Welcome to InteRNA Technologies One of the fastest moving fields in today's biomedical research concerns small non-coding RNAs in general and microRNA (miRNA) in particular. As insights into the role of these RNA species in health and disease are emerging at high speed, so are the opportunities for developing new diagnostic, prognostic and therapeutic applications. InteRNA Technologies is a Dutch early stage drug discovery and development company that develops cancer therapies based on the unique functions of its proprietary miRNAs. It has exclusive access to a large collection of miRNAs that were discovered and patented by its scientific founders Edwin Cuppen and Eugene Berezikov (Hubrecht Institute, Utrecht). InteRNA focuses on the demonstration of their function in a number of cancer indications through functional screens, using its proprietary lentiviral-based miRNA expression library, which is the largest currently available. This approach results in the identification of novel, drugable targets, which provide a steady basis for further validation and drug development. In contrast to small molecules and biologics like antibodies that hit just one single target, our drug development programs aim at developing miRNA-based therapeutics that control signal transduction pathways and biological processes that are known to play a role in cancer initiation, progression and metastasis.
|
News/Press releases: 21-11-2011: InteRNA Technologies announces establishment of Supervisory Board more information 12-09-2011: Silence Therapeutics and InteRNA Technologies sign collaboration to develop novel microRNA therapeutics 29-4-2011: InteRNA Technologies strengthens its R&D team more information 16-11-2010: InteRNA Technologies awarded EUR 1.3 million innovation credit from Dutch government more information 08-07-2010: InteRNA Technologies announces establishment of Scientific Advisory Board more information 02-11-2009: InteRNA Technologies and Dana-Farber Cancer Institute to collaborate on the role of microRNAs in cancer pathways more information 06-07-2009: InteRNA Technologies joins TI Pharma by signing new project to develop novel anti-angiogenic miRNA-based therapeutics more information 22-04-2009: InteRNA Technologies and Radboud University Nijmegen 07-11-2008: InteRNA Technologies and Cenix BioScience Ink Research Agreement for miRNA Drug Discovery more information 06-11-2008: InteRNA Technologies Joins European SIROCCO Consortium to Study RNA Silencing more information 30-10-2008: InteRNA Technologies and VU University Medical Center to Develop microRNA-based Diagnostics and Therapeutics for Cancer more information
Calender of events: June 27-28: 6th Conference on RNAi, miRNA and siRNA, London, UK Speaker: Gregoire Prevost, CDO September 13-14: 11th Annual Biotech in Europe Investor Forum, Zurich, CH Presenter: Roel Schaapveld, CEO September 14-16: ECCP 2011, European Cancer Cluster Partnering, Toulouse, France October 12-13: Translating Oncology Therapies from the Lab to Proof of Concept, Vienna, Austria Speaker: Gregoire Prevost, CDO October 31 - November 2: BIO-Europe 2011, Dusseldorf, Germany
InteRNA will be very pleased to meet you during these events. For appointments or more information, please contact us at info@interna-technologies.com
Vacancies: Currently no vacancies
InteRNA Technologies B.V.
Nijmegen City Centre Jonkerbosplein 52 6534 AB Nijmegen R&D Operations: Hugo R. Kruyt building Padualaan 8 |
|
| © 2007-2011 InteRNA Technologies B.V. - Terms of Use - Contact |  |